Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]
A new study has identified strains of gut microbiota that are associated with more severe strokes and worse post-stroke recovery, revealing that the gut microbiome […]
Neurobiology: Publication in the Journal for Neuroscience Cerebral oedema is a dangerous complication in many brain-related conditions such as strokes. Researchers at the Institute of […]
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against […]
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ATOR-1017, which is […]
Biomedical device passes the litmus test A University of Sydney PhD researcher is developing a cancer and serious disease-detecting biomedical probe that can be made […]
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of […]
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation […]
Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. […]
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall […]
The Group’s recurring revenues (sales plus royalties) grew by 31% to €119 million during the first 9 months. Total revenues amounted to €144 million. The […]
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for […]
Copyright © 2022 | WordPress Theme by MH Themes
